论文部分内容阅读
目的：探讨羟基喜树碱（HCPT）、卡铂（CBP）和足叶乙甙（VP－16）联合治疗常规方案（MVP）失效的晚期非小细胞肺癌的疗效。方法：156例晚期非小细胞肺癌患者接受常规方案2～4周期治疗失效后改用HCPT＋CBP＋VP－16HCE化疗：HCPT 6mg／m2ivd1～5；CBP 300mg／m2ivd1；VP－16 100mgiv d1～5。28天为1周期，每例用药2周期。观察疗效和毒副反应。结果：经2周期治疗后，鳞癌的有效率44．8％。腺癌的有效率38．3％，总有效率42．3％。毒副反应主要是白细胞下降和胃肠道反应。结论：HCE方案是治疗常规方案失效的晚期非小细胞肺癌疗效较高的方案，尤其对复治病例可考虑推荐使用。
Objective: To investigate the efficacy of hydroxycamptothecin (HCPT), carboplatin (CBP) and etoposide (VP-16) in the treatment of advanced non-small cell lung cancer with conventional protocol (MVP) failure. METHODS: 156 patients with advanced non-small cell lung cancer received conventional regimen 2 to 4 cycles of treatment failure and switched to HCPT+CBP+VP-16HCEchemotherapy: HCPT 6 mg/m 2 ivd 1~5; CBP 300 mg/m 2 ivd 1; VP-16 100 mg iv d1 55. 28 days for 1 cycle, 2 cycles for each case. Observe the efficacy and toxicity. Results: After 2 cycles of treatment, the effective rate of squamous cell carcinoma was 44.8%. Adenocarcinoma has an effective rate of 38.3% and a total effective rate of 42.3%. The toxic side effects are mainly leukopenia and gastrointestinal reactions. Conclusion: The HCE regimen is a relatively effective regimen for the treatment of advanced non-small cell lung cancers that have failed conventional procedures. In particular, reconsideration cases can be considered for recommendation.